Nanjing Pharmaceutical Group Company Limited (SHA:600713)
China flag China · Delayed Price · Currency is CNY
5.12
-0.07 (-1.35%)
Nov 18, 2026, 3:00 PM CST

SHA:600713 Balance Sheet

Millions CNY. Fiscal year is Jan - Dec.

Assets

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
1,8793,0504,5632,3732,3282,095
Trading Asset Securities
125.23215.28----
Cash & Short-Term Investments
2,0053,2654,5632,3732,3282,095
Cash Growth
1.12%-28.45%92.28%1.94%11.13%41.32%
Accounts Receivable
23,70816,28915,09816,20919,30415,251
Other Receivables
811.4841.7897.929.7129.2822.86
Receivables
24,51916,33115,19616,23819,33415,274
Inventory
7,2386,9046,2865,7985,7874,518
Other Current Assets
1,2121,9121,7631,6031,8131,571
Total Current Assets
34,97428,41227,80826,01329,26123,458
Property, Plant & Equipment
2,0332,0041,8851,5071,5191,492
Long-Term Investments
266.21269.24283.47237.64206.45254.18
Goodwill
263.7963.2472.1772.1772.1772.17
Other Intangible Assets
314.5209.49215.68218.98245.28268.11
Long-Term Deferred Tax Assets
309.2271.27243.43222.82224.93180.78
Long-Term Deferred Charges
134.4398.2663.0743.3436.8934.24
Other Long-Term Assets
368.77103.18102.7495.5884.69126.24
Total Assets
38,66431,43030,67428,41031,65125,886

Liabilities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Accounts Payable
10,91111,09810,1769,69410,1318,064
Accrued Expenses
131.87335.81369.49363.63438.32379.33
Short-Term Debt
10,0014,7593,7604,5748,4147,036
Current Portion of Long-Term Debt
83.73195.14900.982,2231,409-
Current Portion of Leases
-82.8979.6376.0471.6878.28
Current Income Taxes Payable
197.08174.1387.691.48102.89136.01
Current Unearned Revenue
300.98333.99278.67103.57219.1274.78
Other Current Liabilities
2,6361,5421,4411,4411,4981,756
Total Current Liabilities
24,26218,52017,09418,56622,28417,525
Long-Term Debt
5,1504,1465,3392,1182,2222,628
Long-Term Leases
181.59192.07116.18119.02103.23124.4
Long-Term Unearned Revenue
255.27260.79277.62297.06293.17304.61
Long-Term Deferred Tax Liabilities
55.9958.0459.0555.4154.2469.9
Total Liabilities
29,90523,17822,88621,15524,95620,652

Shareholders' Equity

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Common Stock
1,3081,3091,3091,3101,3101,042
Additional Paid-In Capital
2,4642,4542,4662,4602,4291,380
Retained Earnings
3,4503,3752,9732,6112,2171,778
Treasury Stock
-37.54-51.33-20.9-35.9-38.58-
Comprehensive Income & Other
73.2898.5111.2489.7281.98406.6
Total Common Equity
7,2587,1856,8386,4356,0004,606
Minority Interest
1,5001,068949.87819.73695.03627.46
Shareholders' Equity
8,7598,2537,7887,2556,6955,234
Total Liabilities & Equity
38,66431,43030,67428,41031,65125,886

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Total Debt
15,4169,37510,1969,11012,2199,867
Net Cash (Debt)
-13,412-6,110-5,633-6,737-9,891-7,772
Net Cash Growth
------
Net Cash Per Share
-9.09-4.17-4.32-5.19-7.89-7.46
Filing Date Shares Outstanding
1,3081,3091,3091,3101,3101,042
Total Common Shares Outstanding
1,3081,3091,3091,3101,3101,042
Working Capital
10,7129,89110,7147,4476,9785,933
Book Value Per Share
5.555.495.224.914.584.42
Tangible Book Value
6,6806,9126,5506,1445,6824,266
Tangible Book Value Per Share
5.115.285.004.694.344.10
Buildings
-1,4521,4631,1331,1661,046
Machinery
-962.26928.24890.32839.29762.13
Construction In Progress
-349.69237.27130.0880.23153.4